Compare ClearPoint Neuro Inc (CLPT) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs T Rowe Price Group Inc — how do they compare? ClearPoint Neuro Inc trades at $15.69 (market cap $478.63M), while T Rowe Price Group Inc trades at $118 (market cap $24.87B). The key difference: T Rowe Price Group Inc is far larger — about 52× ClearPoint Neuro Inc's market cap, and T Rowe Price Group Inc pays a 4.48% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CLPT | TROW | |
|---|---|---|
Market Cap | $478.63M | $24.87B |
Sector | Health | Financials |
52-Week High | $29.60 | $120.16 |
52-Week Low | $8.66 | $86.19 |
Enterprise Value | $506.63M | $21.58B |
Dividend Yield | — | 4.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.
Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.
T. Rowe Price (TROW) trades at $113.65, down 4.13% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported June 2026 AUM of $1.89 trillion (PRNewsWire, 2026-07-13), showing steady growth. Recent earnings beat expectations in Q1 2026 with EPS of $2.52 versus $2.33 forecast. Valuation ratios remain attractive with a P/E of 12.19 and ROE of 19.31%, supported by strong cash flow trends.
TROW presents a mixed outlook: analyst consensus is cautious with 63% hold ratings and a $109.17 price target below current levels, but fundamentals like rising net cash flow to $909M in 2026 and a 28.28% net margin offer stability. Key risks include equity outflows and market volatility, while the dividend yield near 4.9% (Investors Business Daily, 2026-06-10) provides income appeal. Upside depends on sustained AUM growth and execution against competition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
